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Abstract
Aims/hypothesis Oestrogens have previously been shown to
exert beta cell protective, glucose-lowering effects in mouse
models. Therefore, the recent development of a glucagon-like
peptide-1 (GLP-1)–oestrogen conjugate, which targets
oestrogen into cells expressing GLP-1 receptors, offers an
opportunity for a cell-specific and enhanced beta cell protec-
tion by oestrogen. The purpose of this study was to compare
the effects of GLP-1 and GLP-1–oestrogen during beta cell
failure under glucolipotoxic conditions.
Methods Male New Zealand obese (NZO) mice were treated
with daily s.c. injections of GLP-1 and GLP-1–oestrogen,
respectively. Subsequently, the effects on energy homeostasis
and beta cell integrity were measured. In order to clarify the
targeting of GLP-1–oestrogen, transcription analyses of
oestrogen-responsive genes in distinct tissues as well as mi-
croarray analyses in pancreatic islets were performed.
Results In contrast to GLP-1, GLP-1–oestrogen significantly
decreased food intake resulting in a substantial weight reduc-
tion, preserved normoglycaemia, increased glucose tolerance
and enhanced beta cell protection. Analysis of hypothalamic
mRNA profiles revealed elevated expression of Pomc and
Leprb. In livers from GLP-1–oestrogen-treated mice, expres-
sion of lipogenic genes was attenuated and hepatic triacyl-
glycerol levels were decreased. In pancreatic islets, GLP-1–
oestrogen altered the mRNA expression to a pattern that was
similar to that of diabetes-resistant NZO females. However,
conventional oestrogen-responsive genes were not different,
indicating rather indirect protection of pancreatic beta cells.
Conclusions/interpretation GLP-1–oestrogen efficiently pro-
tects NZO mice against carbohydrate-induced beta cell failure
by attenuation of hyperphagia. In this regard, targeted delivery
of oestrogen to the hypothalamus by far exceeds the anorex-
igenic capacity of GLP-1 alone.
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Abbreviations
−CH Carbohydrate-free high-fat diet
+CH Carbohydrate-containing high-fat diet
E2 17β-Oestradiol
ERα Oestrogen receptor α
GLP-1 Glucagon-like peptide-1
ISI Insulin sensitivity index
NZO New Zealand obese
Introduction
To compensate for peripheral insulin resistance and glucose
intolerance, pancreatic beta cells start to proliferate and
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increase the biosynthesis and secretion of insulin [1]. The
genetic background and environmental factors limit the ca-
pacity of this compensation, however, and beta cells eventu-
ally fail, leading to type 2 diabetes. In order to prevent this
progression, current research focuses on strategies to protect
beta cells against the toxic microenvironment produced by
circulating carbohydrates and lipids.
Recent data have implicated a beta cell protective role of
oestrogen (17β-oestradiol, E2). E2 has been shown to in-
crease insulin biosynthesis via activation of oestrogen receptor
α (ERα) [2, 3] and to protect beta cells against toxic lipid
intermediates by promoting cell proliferation and inhibition of
lipogenesis and apoptosis [4, 5]. Additionally, systemic E2-
mediated effects on food intake and energy expenditure also
contribute to beta cell protection [6]. In support of these
findings, women generally have a lower prevalence of type
2 diabetes than age-matched males, although this changes
after menopause [7]. In line with these observations, the
EPIC-InterAct study revealed an inverse correlation between
age at menopause onset with the risk of developing type 2
diabetes [8]. Despite all these promising findings, oestrogen
has not been evaluated as a glucose-lowering drug due to its
mitogenic effects in reproductive tissue [9].
Similar to E2, the incretin hormone GLP-1 increases
insulin biosynthesis and survival of beta cells, lowers
food intake and increases glucose uptake in adipose and
muscle tissue [10]. In contrast to more widespread ac-
tion of E2, GLP-1 action is restricted to tissues present-
ing the GLP-1 receptor at its cell surfaces. Recently, we
showed that hybrid molecules of E2 and GLP-1 (GLP-
1–oestrogen) boost the weight lowering effects of GLP-
1 in C57BL/6 mice by targeted delivery of oestrogen to
the hypothalamus [11]. Consequently, lower doses of the
steroid could be used, and the tumourigenic potential of
E2 was masked. Although the body weight lowering
effects of GLP-1-oestrogen were obvious, the question
remained whether the hybrid compound would also be
sufficient to protect beta cells under diabetogenic
conditions.
Similar to humans, New Zealand obese (NZO) mice de-
velop obesity and insulin resistance as a result of hyperphagia,
reduced energy expenditure and insufficient physical activity
[12]. The progression from insulin resistance to type 2 diabe-
tes in NZO mice is largely driven by dietary carbohydrates, as
carbohydrate-free diets fail to induce diabetes in NZO mice
[13]. Taking advantage of this, we previously established a
dietary regimen of 13 weeks of carbohydrate-free high-fat diet
(to induce obesity and insulin resistance) followed by a
carbohydrate-containing high-fat diet that rapidly leads to
hyperglycaemia and beta cell destruction [14]. In this study,
we used the same model system to investigate the glucose-
lowering potential of GLP-1–oestrogen under defined
glucolipotoxic conditions.
Methods
Animals Male NZO/HIBomDife mice (R. Kluge, German
Institute of Human Nutrition, Nuthetal, Germany) were
housed in groups of five per cage (type II macrolon) at a
temperature of 21±1°C, with a 12 h light–dark cycle (lights
on at 06:00 hours). Animals had free access to food and water.
All animal experiments were performed in compliance with
the German animal protection law (TierSchG). The mice were
housed and handled in accordance with the ‘Principles of
laboratory animal care’ [15]. The animal welfare committees
of the DIfE as well as the local authorities (LUGV,
Brandenburg, Germany) approved all animal experiments.
At the age of 5 weeks, animals received a carbohydrate-free
diet (−CH; 20% (wt/wt) protein and 68% (wt/wt) fat, 29 kJ/g).
At the age of 18 weeks, diets were switched to a carbohydrate-
containing diet (+CH; 20% (wt/wt) protein, 28% (wt/wt) fat
and 40% (wt/wt) carbohydrates, 21 kJ/g) for an additional
23 days (Fig. 1a). Treatment with 90 nmol GLP-1, GLP-1–
oestrogen (supplied by R.D. DiMarchi, Indiana University,
Bloomington, IN, USA) or oestrogen per kg body weight
(daily s.c. injections) started 4 days before the diet switch.
Because of the soft texture of the diets, mice had access to
wooden gnawing sticks in order to avoid excessive teeth
growth.
OGTT After an overnight 16 h fasting period, mice received
2 mg glucose per g body weight by oral gavage. At the
indicated time points (Fig. 3b) blood glucose and plasma
insulin were measured, as previously described [16].
Immunohistochemistry of pancreatic islets Pancreatic tissue
excised immediately after exsanguination was fixed in 4%
(wt/vol.) formaldehyde and embedded in paraffin according
to standard procedures. For co-staining of insulin and gluca-
gon, mouse monoclonal anti-insulin (cloneK36AC10, Sigma-
Aldrich, Munich, Germany) and polyclonal rabbit anti-
glucagon (Dako, Hamburg, Germany) antibodies were used.
Alexa Fluor 546-labelled anti-rabbit (1:200) and Alexa Fluor
488-labelled anti-mouse (1:200; Invitrogen, Karlsruhe,
Germany) were used as secondary antibodies. Nuclei were
stained with DAPI.
Pancreatic insulin content For detection of the pancreatic
insulin content, whole pancreases were homogenised in ice-
cold acidic ethanol (0.1 mol/l HCl in 70% ethanol) and incu-
bated for 24 h at 4°C. After centrifugation (16,000×g, 10 min)
insulin was detected in the supernatant fraction using the
Mouse High Range Insulin ELISA (Alpco, Salem, USA).
Insulin sensitivity index Whole body insulin sensitivity was
calculated after the method of Matsuda and DeFronzo [17].
Briefly, fasting blood glucose (G0) and insulin (I0) and the
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mean blood glucose and insulin during OGTT (G and I,
respectively) were recorded. Insulin sensitivity index (ISI)
was calculated (10,000/square root of [G0×I0]×[G×I]).
Laser micro dissection of hypothalamic nuclei and gene
expression analyses Dissected brains were immediately fro-
zen on dry ice, and RNAwas extracted as described previously
[11].
Gene expression analyses in adipose tissue and liver Total
RNA from visceral adipose tissue and liver tissue of mice was
extracted, and cDNA synthesis as well as TaqMan gene ex-
pression assays were performed as described previously [18].
Liver histology and triacylglycerol determination Histological
staining of liver connective tissue was performed using a
Masson–Goldner staining kit (Merck Millipore, Darmstadt,
Germany). For the quantitative determination of triacylglyc-
erol content, livers were homogenised in 10 mmol/l sodium
dihydrogen phosphate, 1 mmol/l EDTA, and 1% (vol./vol.)
polyoxyethylene-10-tridecyl ether, incubated for 5 min at
37°C, and the triacylglycerols in the supernatant fraction were
detected with a commercial kit (RandoxTR-210, Crumlin,
UK).
Islet isolation and transcriptome analysis Isolation of pancre-
atic islets was performed by a modified protocol of Gotoh et al
[19]. Total islet RNA preparation was performed with the
RNAqueous®Micro Kit (Life Technologies, Darmstadt,
Germany). RNA integrity was assessed with the RNA6000
nano kit (Agilent, Santa Clara, CA, USA). Microarray analy-
ses were performed byOakLabs (Hennigsdorf, Germany) on a
Agilent Mouse 8×60 K Chip.
Statistics Statistical differences during treatment were deter-
mined by two-way ANOVA and Bonferroni posttest.
Differences in endpoint measurements were determined by
one-way ANOVA and Newman–Keuls Multiple Comparison
Tests. Contingency of the expression analyses was calculated
by Fisher’s Exact Test. Significance levels were set at
*p<0.05, **p<0.01 and ***p<0.001. Data are presented as
means±SEM. For statistical analysis and for graphical pre-
sentation GraphPad Prism (5.0; GraphPad Software, San
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oestrogen treatment. (a) Study
design. Random blood glucose
(b), bodyweight development (c),
cumulative energy intake (d),
energy intake per day (e), lean
mass (f) and fat mass (g) were
monitored throughout the study.
White circles, −CH control; black
circles, +CH control; white
squares, +CH with GLP-1; black
squares, +CH with GLP-1–
oestrogen. All data are
represented as means±SEM.
Differences compared with the
+CH vehicle group were
calculated by two-way ANOVA.
*p<0.05, **p<0.01, ***p<0.001
vs +CH control group
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Results
GLP-1–oestrogen prevents carbohydrate-induced
hyperglycaemia Male NZO mice were kept on a carbohy-
drate-free, high-fat diet (−CH) until the age of 18 weeks
(Fig. 1a). Due to this dietary regimen, NZO mice become
obese and insulin resistant, but are protected from developing
diabetes [14]. Afterwards, the diet was changed to a
carbohydrate-containing high-fat diet (+CH), which induces
a rapid hyperglycaemia and finally beta cell destruction in a
synchronised manner [14] (Figs 1b, 2a). GLP-1-treated ani-
mals displayed the same increase in blood glucose upon
carbohydrate feeding as the vehicle-treated +CH control
group (Fig. 1b). In contrast, GLP-1–oestrogen-treated animals
exhibited normal blood glucose levels similar to vehicle-
treated animals that continued with the –CH diet. Treatment
with GLP-1 led to a modest reduction in body weight by 6.1±
3.4% from baseline (72±10 g), while GLP-1–oestrogen re-
duced body weight by 12.8±1.8% (Fig. 1c). The cumulative
energy intake of the GLP-1 group only differed at days 19 and
23; animals of the GLP-1–oestrogen group already consumed
significantly fewer calories after 2 days of +CH feeding
(Fig. 1d). This decreased total amount of consumed calories
was largely due to a transient and robust reduction in energy
intake during the first 10 days of GLP-1–oestrogen treatment
(Fig. 1e). Importantly, the decrease in body weight in the
GLP-1 group was due to loss of lean mass (Fig. 1f, g). In
contrast, GLP-1–oestrogen-treated animals mainly lost fat
mass (Fig. 1f, g).
Pancreatic islets are protected by GLP-1–oestrogen against
carbohydrate-induced destruction Histology of the pancreat-
ic islets at the end of the study revealed substantial islet
destruction in +CH animals (Fig. 2a). While GLP-1 treatment
led to an intermediate phenotype with a clear disruption of
normal islet cytoarchitecture, islets from GLP-1–oestrogen-
treated animals displayed normal islet morphology (Fig. 2a).
To that end, pancreatic insulin content was markedly reduced
in response to the carbohydrate intervention (+CH; Fig. 2b).
This effect was only partially prevented by GLP-1 (p=0.105);
GLP-1–oestrogen resulted in a significant (p=0.034) increase
in pancreatic insulin content (Fig. 2b). While GLP-1 treatment
alone failed to improve oral glucose tolerance, GLP-1–
oestrogen-treated animals displayed improved glucose toler-
ance (Fig. 3a). Strikingly, fasting glucose levels were highest
in −CH control mice, and insulin levels were higher, although
not significantly, throughout the glucose tolerance test. This
effect could reflect the markedly insulin resistant hepatic
glucose output in NZO mice on the −CH diet [13]. Although
not significant, both GLP-1 and GLP-1–oestrogen animals
showed lower plasma insulin values during OGTT (Fig. 3b).
Insulin sensitivity, as measured with the Matsuda index [17],
was improved upon treatment with the hybrid compound
(Fig. 3c).
Oestrogen improves islet function but not glucose
tolerance As effects of GLP-1–oestrogen on diabetes preven-
tion were very much different from that of GLP-1, we per-
formed additional experiments with oestrogen. In oestrogen-
treated animals, the carbohydrate-induced rise in blood glucose
was reduced but not fully abolished (Fig. 4a). Furthermore,
oestrogen treatment did not reduce body weight or energy
intake (Fig. 4b, c) and improved neither glucose tolerance
nor insulin sensitivity (Fig. 4d–f). Interestingly, pancreatic
islets of oestrogen-treated mice displayed largely preserved
cytoarchitecture and unaltered insulin content (Fig. 4g, h).
Reduced food intake is associated with increased anorexigenic
signalling GLP-1–oestrogen treatment resulted in a transient
but substantial reduction in food intake during the first week
of treatment (Fig. 1e). Both GLP-1–oestrogen and oestrogen
treatment increased the hypothalamic expression of
oestrogen-responsive Trim25 [20] (15.5±1.3- and 18.2±1.4-
fold, respectively) in comparison with vehicle-treated +CH
control animals, indicating that GLP-1-bound oestrogen is


































Fig. 2 Pancreatic islet integrity. (a) Staining of pancreatic slices against
insulin (green), glucagon (red) and nuclei (blue). (b) Pancreatic insulin
content (n=3 animals per group). All data are represented as means±
SEM. Differences compared with the −CH or +CH vehicle group (as
indicated) were calculated by Student’s t test. *p<0.05 vs −CH control
and +CH control, respectively. G, GLP-1; GE, GLP-1–oestrogen
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extent, GLP-1 treated animals also displayed elevated Trim25
expression (3.8±0.9-fold). The carbohydrate challenge sup-
pressed Pomc expression, whereas GLP-1 and oestrogen
prevented the drop in Pomc mRNA levels (Fig. 5b). GLP-1–
oestrogen increased Pomc expression compared with vehicle-
treated and GLP-1-treated animals (17.8±5.4- and 2.9±0.9-
fold, respectively; Fig. 5b). Leptin receptor (Leprb) expres-
sion was increased to a similar extent by all treatments (1.8±
0.1-, 2.0±0.2- and 2.3±0.2-fold, respectively; Fig. 5c).
Expression of orexigenic Cart (also known as Cartpt) and
ca






















































Fig. 3 OGTT. (a) Blood glucose excursion and (b) plasma insulin values
(n=5–15 animals per group). (c) ISI measured after Matsuda [17]. White
circles,−CHcontrol; black circles, +CH control; white squares, +CHwith
GLP-1 (G); black squares, +CHwith GLP-1–oestrogen (GE). All data are
represented as means±SEM. Differences compared with the +CH vehicle
group were calculated by two-way ANOVA (a, b) and one-way ANOVA
























































































































































Fig. 4 Oestrogen treatment
during carbohydrate feeding.
Measurements of random blood
glucose (a), body weight
development (b) and cumulative
energy intake (c). Blood glucose
excursion (d) and plasma insulin
(e) during OGTT. (f) ISI
measured after Matsuda [17].
(g) Staining of pancreatic slices
against insulin (green), glucagon
(red) and nuclei (blue).
(h) Pancreatic insulin content.
White circles, −CH control; black
circles, +CH control; black
triangles, +CH with oestrogen
(E). All data are represented as
means±SEM (n=6–10 animals
per group). Differences compared
with the +CH vehicle group were
calculated by two-way ANOVA
(a–e) and one-way ANOVA
(f, h), respectively. **p<0.01
vs +CH control group
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Npy was not different (Fig. 5d, e). However, expression of
orexigenic Agrp was elevated with GLP-1 and GLP-1–
oestrogen (4.4±0.9- and 3.0±0.6-fold, respectively; Fig. 5e).
Attenuation of lipogenic pathways in GLP-1–oestrogen-treated
mice Histological analyses revealed large vacuoles, presum-
ably lipid droplets, in livers of control, GLP-1- and oestrogen-
treated mice (Fig. 6a). In contrast, livers of mice that received
GLP-1–oestrogen showed substantially improved liver mor-
phology. Accordingly, hepatic triacylglycerol accumulation
was attenuated in GLP-1–oestrogen-treated mice, but also
oestrogen-treated mice revealed lower triacylglycerol levels
(Fig. 6b). Carbohydrate feeding substantially increased hepat-
ic expression of lipogenic Acaca, Fasn and Scd1 (Fig. 6c–e).
GLP-1–oestrogen reduced expression of Acaca and Fasn by
39±7.8 and 52±9.3%, respectively. Neither of the treatments
altered expression of Scd1 (Fig. 6c). Importantly, hepatic
expression of Trim25 was not different among the treatment
groups (electronic supplementary material [ESM] Fig. 1a).
Because loss of fat mass was a major part of the
GLP-1–oestrogen phenotype (Fig. 1g), we also investi-
gated the expression of the above mentioned genes in
visceral adipose tissue. Although the adipose expression
pattern was similar to the hepatic one, no significant
differences among the groups were observed (Fig. 6f–h).
Also, in adipose tissue, expression of Trim25 was not
different (ESM Fig. 1b), demonstrating that liver and
adipose tissue are not a direct target site of action of the
GLP-1–oestrogen hybrid.
GLP-1 and GLP-1–oestrogen treatment affects the tran-
scriptome of pancreatic islets In order to investigate whether
diabetes protection could be due to direct effects of GLP-1–
oestrogen on pancreatic islets, we studied the islet tran-
scriptome 2 days after diet switch (6 days after treatment
initiation). At this time point, the rise in blood glucose and
suppression of Akt signalling is observed in untreated NZO
mice [14]. In the islets of GLP-1-treated animals, 120 mRNAs
were differentially expressed compared with the islets of the +
CH group (signal intensity>50, log fold change>|1.0| and
p<0.05; ESM Table 1). Similarly, in islets of GLP-1–
oestrogen mice, 43 mRNAs were differentially expressed
(ESM Table 2). Of these mRNAs, 21 were upregulated
(Table 1) and 13 were downregulated (Table 2) by GLP-1–
oestrogen treatment only, indicating effects specific for the
hybrid compound.
Oestrogen-specific effects on pancreatic islets could also be
the reason for lower diabetes prevalence in female NZO mice
[16], which do not display hyperglycaemia upon diet switch
(Fig. 7a). In order to narrow down oestrogen-specific effects
of the hybrid compound, we performed transcriptome analy-
ses comparing pancreatic islets from male vs female NZO
mice 2 days after diet switch. In islets of NZO females, 273
genes were differentially expressed compared with that of
male mice (signal intensity>50, log fold change>|1.0| and
p<0.05; ESM Table 3). Twelve (29%) of the genes altered
by GLP-1–oestrogen were also differentially expressed in
female NZO mice. Contingency analyses exclude an overlap
by chance (Fisher’s Exact Test, OR 62.49, p=2.2×10−16).
However, there was also an overlap of 19 genes (16%) be-
tween those genes that were altered with GLP-1 treatment and
those that differed between females and males (OR 24.14, p=
2.2×10−16). Three genes (Gcat, Psat1 and Uap1l1) were
enriched in islets of GLP-1–oestrogen-treated male mice and
cba
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Fig. 5 Hypothalamic gene
expression. (a) Trim25, (b) Pomc,
(c) Leprb, (d) Cart, (e) Npy and
(f) Agrp (n=7–11 animals per
group). All data are represented as
means±SEM. Differences
compared with the +CH vehicle
group were calculated by one-
way ANOVA. *p<0.05,
**p<0.01, ***p<0.001 vs +CH
control group. G, GLP-1; GE,
GLP-1–oestrogen; E, oestrogen
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female mice (Fig. 7b). Expression of Aqp4, Gprin3, Sh2d5
and Txnip was reduced in islets of females, as well as in islets
of male mice treated with both GLP-1 and GLP-1–oestrogen
(Fig. 7c). Expression of 4931429I11Rik, Arrdc4, Gsto2,
Scarf2 and Slc22a2 was reduced only in islets from females
and GLP-1–oestrogen-treated male mice (Fig. 7c).
Discussion
In this study, we evaluated the potential of oestrogen-coupled
GLP-1 to protect beta cell function under glucolipotoxic con-
ditions in diabetes-prone male NZOmice. We show that GLP-
1–oestrogen fully prevented the onset of hyperglycaemia and
reduced body weight due to a substantially decreased food
intake, indicating the hypothalamus to be the main site of
GLP-1–oestrogen action. Subsequently, GLP-1–oestrogen
protected the mice against carbohydrate-induced beta cell
failure, increased glucose tolerance and insulin sensitivity
and affected the islet transcriptome. Thus, compared with
GLP-1, low-dose GLP-1–oestrogen revealed superior efficacy
to preserve beta cell integrity and function under diabetogenic
conditions.
The findings of the present study indicate that the combi-
nation of GLP-1 and oestrogen in a hybrid molecule possesses
a glucose-lowering potential that exceeds the potential of
either one of the single molecules. Recently we showed that
oestrogen has beta cell protective effects in female NZOmice,
as ovariectomised animals displayed elevated blood glucose
levels and eventually an increased prevalence of type 2 dia-
betes compared with sham-operated control mice [16].
Furthermore, treatment of oestrogen-deficient mice with





































































































































































Fig. 6 Effects on liver and
visceral adipose tissue. (a)
Masson–Goldner staining of liver
sections with cytoskeletal
elements and cytoplasma
(reddish), nuclei (dark blue) and
fibrotic areas (green to blue). (b)
Hepatic triacylglycerol content.
Gene expression of Acaca, Fasn
and Scd1 in liver (c–e) and
adipose tissue (f–h) (n=3–6
animals per group). All data are
represented as means±SEM.
Differences compared with the
+CH vehicle group were
calculated by one-way ANOVA.
*p<0.05, **p<0.01, ***p<0.001
vs −CH control and +CH control,
respectively. G, GLP-1; GE,
GLP-1–oestrogen; E, oestrogen
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cells against streptozotocin-induced beta cell apoptosis and
the collapse of insulin production [5]. In the present study,
transcriptome analyses did not indicate direct beta cell protec-
tion by GLP-1–oestrogen at the given dose, as neither Trim25
nor Acaca, Fasn and Scd1 were differentially expressed in
pancreatic islets of GLP-1–oestrogen-treated mice. The later
three lipogenic genes mentioned have previously been shown
to be repressed in pancreatic islets of Zucker diabetic fatty rats
upon oestrogen treatment [4]. Still, our transcriptome analyses
indicated several alterations of the pancreatic expression pat-
tern that could be protective, even as secondary effects of
hypothalamic GLP-1–oestrogen action. Particularly, the α-
arrestin Txnip is well known as a key player in pancreatic beta
cell biology, as it is increased in diabetic islets and induces
beta cell apoptosis [21, 22]. The GLP-1–oestrogen-mediated
suppression of Txnip could be mediated via GLP-1 as was
Table 1 Genes selectively upregulated by GLP-1–oestrogen treatment
Gene symbol Gene name Target name Log2 ratio p value
n.d. n.d. ENSMUST00000090946 1.09486 0.0402206
Ddn Dendrin NM_001013741 1.07733 0.0024692
Uap1l1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 NM_001033293 1.07954 0.0140211
Vmn2r3 Vomeronasal 2, receptor 3 NM_001104614 1.13616 0.0201833
C2cd4a C2 calcium-dependent domain containing 4A NM_001163143 1.18812 0.0451038
Psat1 Phosphoserine aminotransferase 1 NM_001205339 1.0513 0.00834699
Lce1k Late cornified envelope 1K NM_001254760 1.43164 0.0408397
Hemt1 Haematopoietic cell transcript 1 NM_010416 1.10077 0.0423324
Olfr48 Olfactory receptor 48 NM_010990 1.21633 0.0475563
Dapp1 Dual adaptor for phosphotyrosine and 3-phosphoinositides 1 NM_011932 1.07411 0.0328786
Ar Androgen receptor NM_013476 1.58906 0.0127427
Pvalb Parvalbumin NM_013645 1.0195 0.00177101
Gcat Glycine C-acetyltransferase (2-amino-3-ketobutyrate-coenzyme A ligase) NM_013847 1.08209 0.0187919
Chst11 Carbohydrate sulfotransferase 11 NM_021439 1.06272 0.0296596
Ankrd22 Ankyrin repeat domain 22 NM_024204 1.00047 0.0168974
Olfr521 Olfactory receptor 521 NM_146356 1.76128 0.0398948
Zfp846 Zinc finger protein 846 NM_172919 1.03213 0.00931397
Esyt3 Extended synaptotagmin-like protein 3 NM_177775 1.31178 0.000172183
Arl9 ADP-ribosylation factor-like 9 NM_206935 1.19194 0.0302383
Pinc Pregnancy induced noncoding RNA NR_003202 1.11694 0.0441702
Gm11213 Predicted gene 11213 NR_028584 1.11473 0.0430175
n.d., not determined
Table 2 Genes selectively downregulated by GLP-1–oestrogen treatment
Gene symbol Gene name Target name Log2 ratio p value
Trpm1 Transient receptor potential cation channel, subfamily M, member 1 NM_001039104 −1.3242 0.0442979
Arrdc4 Arrestin domain containing 4 NM_001042592 −1.7883 0.0177293
Fbxo34 F-box protein 34 NM_001146085 −1.29837 0.000724301
Ccdc138 Coiled-coil domain containing 138 NM_001162956 −1.19938 0.0339959
Slc22a2 Solute carrier family 22 (organic cation transporter), member 2 NM_013667 −1.67727 0.0484448
Ramp1 Receptor (calcitonin) activity modifying protein 1 NM_016894 −1.14732 0.0336212
Gsto2 Glutathione S-transferase omega 2 NM_026619 −1.11477 0.0204581
Hist2h4 Histone cluster 2, H4 NM_033596 −1.23263 0.0201723
Trim7 Tripartite motif-containing 7 NM_053166 −1.04176 0.0152357
6330416G13Rik RIKEN cDNA 6330416G13 gene NM_144905 −1.09125 0.00117735
Olfr522 Olfactory receptor 522 NM_146952 −1.15184 0.0294387
Scarf2 Scavenger receptor class F, member 2 NM_153790 −1.64384 0.00309493
Cox6b2 Cytochrome c oxidase subunit VIb polypeptide 2 NM_183405 −1.36337 0.00313767
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shown for exenatide [23]. Additionally, oestrogen-mediated
repression of Txnip was demonstrated in vitro and in vivo
[24]. Still, inhibition of Txnip alone was not sufficient to
prevent beta cell failure, as seen in GLP-1-treated animals.
Interestingly, a second α-arrestin, Arrdc4, is suppressed in
islets after GLP-1–oestrogen treatment. This effect appears
to be mediated by oestrogen, because also females, but not
GLP-1-treated males, exhibited this lower expression.
Whether Arrdc4 has similar adverse effects as Txnip in beta
cells is not known; however, our data suggest that inhibition of
both genes in GLP-1–oestrogen-treated mice participates in
beta cell protection.
GLP-1-bound oestrogen stimulated anorexigenic signal-
ling that was far more effective than GLP-1 alone. The hybrid
compound reaches the brain, as GLP-1–oestrogen treatment
increased hypothalamic expression of oestrogen-responsive
Trim25 [20] to a similar extent as oestrogen alone.
Nevertheless, induction of Pomc expression was clearly
highest in GLP-1–oestrogen-treated animals, indicating that
oestrogen only affects appetite in NZO mice when combined
with GLP-1. Brain-targeted oestrogen not only affects Pomc
expression but also has been shown to increase the firing rate
ofPomc-expressing neurons, resulting in substantial reduction
in food intake, and subsequently body weight [25]. Therefore,
our data are in line with these published observations and
suggest that reduced caloric intake via pro-opiomelanocortin
(POMC) activation is the major mechanism leading to
improved glycaemia in GLP-1–oestrogen-treated NZO mice.
Indeed, several studies have proven that caloric restriction is
sufficient to improve glucose tolerance and insulin sensitivity
in humans and animal models [26, 27]. Especially, liver fat
decreases within days upon caloric restriction and contributes
to improved glucose homeostasis [28]. In contrast to Pomc,
expression of anorexigenic Leprb was elevated in GLP-1-,
GLP-1–oestrogen- and oestrogen-treated mice. In previous
studies, NZO mice have been shown to be severely leptin
resistant and this leptin resistancemight be due to the presence
of several polymorphisms in the Lepr gene [29, 30].
Therefore, the absence of any anorexigenic signalling in
GLP-1- or oestrogen-treated NZO mice could be illustrative
of an impaired leptin signalling in NZO mice, despite
increased Lepbr expression.
GLP-1–oestrogen treatment did not alter Trim25 expres-
sion in liver or visceral adipose tissue. This is opposite to the
findings in the hypothalamus and similar to that in pancreatic
islets, and could be explained by the lack of GLP-1 receptor
expression in these tissues [31, 32]. Interestingly, carbohy-
drate feeding also suppressed Trim25 expression in the hypo-
thalamus, but not in the periphery. The mechanism behind this
observation, as well as the tissue-specific counter regulation
by oestrogen, is not known and data on a metabolic function
of Trim25 are missing. Still, both liver and adipose tissue
displayed a substantial reduction in their lipid content, indi-
cating a secondary effect through central actions of GLP-1–
oestrogen that ultimately influences whole body metabolism.
Furthermore, we observed an inhibition of lipogenic genes in
the liver. This is in line with previous studies showing that
oestrogen treatment of ovariectomised mice and high-fat diet
(HFD)-fed mice resulted in inhibition of lipogenic gene ex-
pression in liver and adipose tissue [33, 34]. These published
data also indicated enhanced lipolytic response and β-oxida-
tion, which was not assessed in our study and would need
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Fig. 7 Gene expression in
pancreatic islets 2 days after
switch to +CH. (a) Blood glucose
excursion in male vs female NZO
mice upon switch to +CH diet.
Genes being upregulated (b) and
downregulated (c), respectively,
in NZO females and GLP-1–
oestrogen-treated males (n=2–3
animals per group). Black circles,
+CH males; white diamonds,
+CH females. White bars, males;
light grey bars, females; dark grey
bars, males with GLP-1; black
bars, males with GLP-1–
oestrogen. Differences in blood
glucose were calculated by two-
way ANOVA. Expression
differences were calculated by
Student’s t test. *p<0.05,
**p<0.01, ***p<0.001 vs
control
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further investigation to clarify. However, both studies as-
sumed direct effects of oestrogen on both tissues. The data
in the present study suggest that a major part of the oestrogen
action is via the central nervous system, as a direct action of
GLP-1–oestrogen on liver and adipose tissue are more likely
to be excluded. This concept is supported by the finding that
specific deletion of hypothalamic ERα is sufficient to reduce
whole body energy expenditure and induce hyperphagia in
female mice, resulting in obesity and impaired glucose toler-
ance [35, 36].
In summary, oestrogen-coupled GLP-1 displays superior
efficacy in preventing the onset of diet-induced diabetes than
GLP-1 alone. In NZO mice, this protective effect is due to
central attenuation of hyperphagia, resulting in systemic im-
provement of glucose tolerance and insulin sensitivity.
Therefore, hybrid compounds like GLP-1–oestrogen might
be the basis for novel therapeutic options for treating type 2
diabetes mellitus more efficiently.
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